Ampligen

Rintatolimod (tradename Ampligen) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a TLR3 agonist which stimulates the production of interferons and tumor necrosis factors. It is manufactured by Hemispherx Biopharma.

It has been shown to raise natural killer cell function.

Notable studies

 * 2015, Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome

Learn more

 * Wikipedia - Rintatolimod
 * 2016, Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement (see also NIH Post-Infectious ME/CFS Study)
 * 2016, Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear
 * 2015, FDA Response Letter Regarding Approval of Ampligen for ME/CFS
 * 2015, Ampligen price more than doubles - Available soon in Europe
 * 2015, FDA Approval of MS Drug Puts Ampligen Back In Play
 * 2013, Ampligen and biomarkers: my testimony to FDA Dec 2012
 * 2012, Ampligen I: Effectiveness
 * 1994, The Aids Drug No One Can Have Mindy Kitei (see also Mindy Kitei)
 * 1990, Chronic Fatigue Syndrome